Elmind Capital
Elmind Capital reported 35 stocks worth $398M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are COGT (11.4%), SNDX (10.2%) and CLDX (9.3%). Compared with Q1 2026, the fund opened new positions in LEGN, SMMT and INSM, added to CLDX, RLAY and PCVX, trimmed VERA, BCRX and MBX and sold out of CGON and EWTX.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 3 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  COGT Cogent Biosciences Inc | $45.3M | 11.4% | 1.2M | No change | 3 of 3 | |
| 2 |  SNDX Syndax Pharmaceuticals Inc | $40.6M | 10.2% | 1.9M | No change | 3 of 3 | |
| 3 |  CLDX Celldex Therapeutics Inc | $36.8M | 9.3% | 990K | +125K (+14%) | 3 of 3 | |
| 4 |  RLAY Relay Therapeutics Inc | $27.4M | 6.9% | 1.5M | +928K (+173%) | 3 of 3 | |
| 5 |  PCVX Vaxcyte Inc | $26.3M | 6.6% | 452K | +136K (+43%) | 3 of 3 | |
| 6 |  VERA Vera Therapeutics Inc | $18.7M | 4.7% | 437K | −46K (−10%) | 3 of 3 | |
| 7 |  PHVS Pharvaris N V | $18.2M | 4.6% | 526K | +50K (+11%) | 3 of 3 | |
| 8 |  VRDN Viridian Therapeutics Inc | $18.1M | 4.5% | 985K | +450K (+84%) | 3 of 3 | |
| 9 |  CTMX Cytomx Therapeutics Inc | $17.1M | 4.3% | 4.5M | No change | 3 of 3 | |
| 10 |  TVTX Travere Therapeutics Inc | $16.6M | 4.2% | 293K | +115K (+65%) | 3 of 3 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026
Reported value
last 3 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Elmind Capital 13F FAQ
What does Elmind Capital own?
Elmind Capital reported 35 stocks worth $398M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are COGT (11.4%), SNDX (10.2%) and CLDX (9.3%). The table above lists every position in the filing (the top 10 without an account).
What did Elmind Capital buy and sell in Q2 2026?
Compared with Q1 2026: 6 new positions, 9 added to, 6 trimmed and 5 sold out. New positions include LEGN, SMMT and INSM. It sold all of CGON and EWTX.
When will Elmind Capital file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Elmind Capital's portfolio worth?
The Q2 2026 filing reports $398M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.